

June 14, 2007

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126

### Canadian Levofloxacin Patent Upheld by Federal Appeal Court

TOKYO – DAIICHI SANKYO CO., LTD. (President & CEO: Takashi Shoda), one of Japan's leading pharmaceutical companies, today announced that the Canadian Federal Appeal Court affirmed the decision of the Canadian Federal Court in Toronto, which held that Daiichi Sankyo's patent (No. 1,304,080) on its antibacterial agent, levofloxacin, is valid and infringed by generic levofloxacin tablets of Novopharm Limited. As a result of this decision, generic drug manufacturer Novopharm Limited is enjoined from selling, offering for sale or otherwise dealing with a generic version of levofloxacin products including tablets in the Canadian market until the expiry of Daiichi Sankyo's patent on June 23, 2009.

Daiichi Sankyo's licensee for levofloxacin tablets and intravenous injection in Canada is Janssen-Ortho Inc., who markets these products in Canada under the trade mark LEVAQUIN®. Janssen-Ortho Inc. was a co-plaintiff in this litigation.

### DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED was established on September 28, 2005 as the joint holding company of two major Japanese pharmaceutical companies – Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. DAIICHI SANKYO aims to become a Global Pharma Innovator, continuously generating innovative drugs and services and maximizing its corporate value. DAIICHI SANKYO has a broad range of major drug products on the Japanese market, including the antihypertensive Olmetec® (olmesartan medoxomil) and the synthetic antibacterial agent Cravit® (levofloxacin) and strongly promotes providing drug information. DAIICHI SANKYO specializes in

the field of cardiovascular disease and has used their cumulative knowledge and expertise as a foundation for developing an abundant product lineup and R&D pipeline.

For further details, please refer to the company Web site, at

<http://www.daiichisankyo.com/>